Tesamorelin powder is a high-purity synthetic polypeptide with a molecular weight of 5135.86 Da. Produced via solid-phase peptide synthesis technology and purified by high-performance liquid chromatography (HPLC), this powder achieves a purity of over 98%. It presents as a white to off-white crystalline substance with no irritating odor and excellent solubility, capable of dissolving rapidly in sterile water or buffer solutions to form a clear liquid.
As an FDA-approved therapeutic agent for HIV-associated lipodystrophy, the powder is administered via subcutaneous injection. It can significantly reduce visceral fat accumulation, while improving insulin sensitivity and lipid metabolism. In the field of scientific research, it is widely used for establishing metabolic disease models and investigating anti-aging mechanisms.
Our Products Form
Tesamorelin COA
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide, characterized by the abnormal accumulation of fat in the liver. It can progress to non-alcoholic steatohepatitis (NASH), liver cirrhosis, and even hepatocellular carcinoma. With the epidemic of obesity and metabolic syndrome, the incidence of NAFLD has been on a steady rise. However, there are currently no specific drugs approved by the FDA or EMA for its treatment. As a growth hormone-releasing hormone (GHRH) analog, Tesamorelin powder was initially approved for the treatment of abdominal fat accumulation in HIV-infected patients, and in recent years, it has demonstrated unique application potential in the field of NAFLD.
Pathological Mechanisms and Therapeutic Challenges of NAFLD
The pathogenesis of NAFLD is closely associated with insulin resistance, increased release of free fatty acids (FFA), excessive hepatic lipid synthesis, and oxidative stress. The core pathological processes include the following:
Fat Accumulation:
The liver takes up more FFAs than it can oxidize and secrete, leading to the accumulation of triglycerides (TG) in hepatocytes.
Inflammation and Fibrosis:
Fat accumulation triggers oxidative stress and inflammatory responses, activating hepatic stellate cells (HSC) and promoting collagen deposition and fibrosis.
Metabolic Disorders:
NAFLD is often accompanied by insulin resistance, dyslipidemia, and hypertension, forming a vicious cycle.
Traditional therapeutic approaches (such as lifestyle interventions, weight-loss medications, and insulin sensitizers) have limited efficacy, and there is a lack of targeted drugs for fibrosis and inflammation. Therefore, the development of drugs that can simultaneously reduce fat accumulation, inhibit inflammation, and alleviate fibrosis has become a research hotspot.
Mechanism of Action of it: From Lipid Metabolism to Gene Regulation
By binding to GHRH receptors in the anterior pituitary gland, it stimulates the secretion of endogenous growth hormone (GH), which in turn promotes the synthesis of insulin-like growth factor-1 (IGF-1) in the liver. Its mechanism of action involves multi-level regulation:
Enhancing Mitochondrial Fat Oxidation
Regulation of Gene Expression:
Studies have shown that the product can upregulate the expression of fat-burning-related genes in mitochondria (e.g., oxidative phosphorylation genes), enhancing the ability of hepatocytes to oxidize FFAs and reducing lipid accumulation.
Activation of Metabolic Pathways:
It promotes fatty acid β-oxidation and inhibits the expression of key enzymes involved in lipid synthesis (e.g., fatty acid synthase, FASN) by activating the AMPK/PPARα signaling pathway.
Inhibiting the Fibrosis Process
Downregulation of Fibrosis-related Genes: It treatment can significantly reduce the expression of genes associated with collagen deposition (e.g., COL1A1, TGF-β1), blocking the activation of hepatic stellate cells.
Inhibition of Inflammatory Responses: It reduces the release of pro-inflammatory cytokines (e.g., TNF-α, IL-6) by downregulating the NF-κB pathway, alleviating liver inflammation.
Regulating Cell Proliferation and Cancer Risk
Inhibition of Excessive Cell Repair: It can downregulate genes related to cell division (e.g., Cyclin D1), reducing hepatocyte proliferation and potentially lowering the risk of hepatocellular carcinoma.
Upregulation of Genes Associated with Favorable Cancer Prognosis: Studies have found that the expression of genes linked to positive cancer outcomes (e.g., BRCA1, PTEN) is increased in patients receiving treatment, suggesting a potential anti-cancer effect.
Clinical Evidence: Expansion from HIV-associated NAFLD to the General Population
Treatment of NAFLD in HIV-infected Patients
HIV-infected patients are prone to lipodystrophy due to long-term antiretroviral therapy (ART), with the prevalence of NAFLD as high as 25%–40%. Multiple randomized controlled trials (RCTs) have confirmed the following benefits:
Improvement in Fibrosis: The proportion of patients with stable or improved fibrosis scores in the treatment group is significantly higher than that in the placebo group (88% vs. 67%).
Decrease in Inflammatory Markers: Levels of liver enzymes such as ALT and AST, as well as inflammatory factors (e.g., CRP), are significantly reduced.
Potential Application in Non-HIV Populations
Although large-scale trials of Tesamorelin powder in patients with NAFLD in the general population have not yet been conducted, mechanistic studies support its expanded indication:
Comorbidity with Metabolic Syndrome: NAFLD often coexists with obesity and diabetes. By improving insulin resistance and dyslipidemia, it may achieve a "multi-effect with one drug" outcome.
Universality of Gene Expression Regulation: Liver biopsy studies in HIV-negative patients have shown that it can also regulate the expression of genes related to fat oxidation and fibrosis, indicating that its mechanism of action is not affected by HIV status.
Safety and Tolerability: Balancing Efficacy and Risk
It has an overall favorable safety profile. Common adverse reactions are mild injection site reactions (e.g., erythema, pain) and joint pain, with an incidence rate of approximately 15%–20%. The following risks need to be noted:
Blood Glucose Fluctuations: GH may transiently elevate blood glucose levels by promoting hepatic glucose output, but the beneficial effect of reduced FFA release through fat decomposition can offset this effect during long-term treatment.
Contraindications: It is contraindicated in patients with active malignancies, a history of pituitary tumors or pituitary surgery, and pregnant women.
Monitoring Recommendations: During treatment, regular monitoring of blood glucose, blood lipids, IGF-1 levels, and liver ultrasound/MRI is required to evaluate efficacy and safety.
Future Directions: Precision Intervention and Combination Therapy Strategies
With the deepening understanding of the heterogeneity of NAFLD, the application of it is shifting from a "one-size-fits-all" approach to individualized precision intervention:
Biomarker-guided Stratified Therapy: Identify patient subgroups most likely to benefit by detecting GHRH receptor expression levels, GH/IGF-1 axis activity, or visceral fat area.
Synergistic Enhancement via Combination Therapy: Explore the synergistic effects of it with GLP-1 receptor agonists (e.g., semaglutide), SGLT-2 inhibitors (e.g., empagliflozin), or statins to further improve metabolic indicators.
Verification of Long-term Efficacy and Safety: Conduct larger-scale, longer-duration RCTs to clarify the preventive effect of it on end-stage events such as liver cirrhosis and hepatocellular carcinoma.
Tesamorelin Powder is a high-purity lyophilized powder formulation, primarily intended for the preparation of solutions for subcutaneous injection. It is imperative to strictly follow standardized operating procedures to ensure that the biological activity of the polypeptide is preserved, the dosage administered is accurate, and medication safety is guaranteed.
Reconstitution Procedure: Gentle Reconstitution to Preserve Activity
Reconstitution is a critical step for ensuring drug efficacy, and vigorous manipulation that may cause polypeptide degradation must be avoided. Take one vial of the product lyophilized powder (standard specification: 2 mg) and reconstitute it with 1 mL of the dedicated sterile water for injection. Slowly inject the solvent along the inner wall of the ampoule to prevent air bubbles caused by directly flushing the powder. After injection, gently roll the ampoule to fully dissolve the powder; shaking or vortexing is strictly prohibited.
Allow the reconstituted solution to stand for a short while and observe its state. The solution must be clear, colorless, particle-free, and non-turbid. If precipitation or flocculation occurs, the solution must be discarded immediately and must not be used. The reconstituted solution should be administered right away and should not be left at room temperature for more than 30 minutes to prevent the attenuation of polypeptide activity.
Key Precautions: Avoiding Risks to Ensure Safety
The only solvent permitted for reconstitution is the dedicated sterile water for injection. Other vehicles such as normal saline or glucose solution must not be used, as they may induce polypeptide aggregation or loss of activity.
The powder should be stored in a sealed container under refrigerated conditions at 2–8 °C. Any unused reconstituted solution must not be refrigerated or frozen and should be discarded directly.
Disposable gloves must be worn during the operation to avoid direct contact between hands and the powder or reconstituted solution, thus preventing contamination. If accidental contact with the skin or mucous membranes occurs, rinse the affected area thoroughly with a large amount of clean water immediately.
In addition, the dosage must be adjusted strictly in accordance with medical advice. Unauthorized increases or reductions in dosage are not allowed to ensure compliance with medication guidelines.
FAQ
How long does it take for it to start working?
+
-
Within 1-2 weeks, you should begin to experience reductions in your visceral fat. At 4-6 weeks, your abdominal fat should begin to reduce significantly, and your lipid profiles ought to improve. Improvements in muscle mass are often seen at this point as well.
How to reconstitute tesamorelin 2mg?
+
-
Reconstitute 1 vial of EGRIFTA SV lyophilized powder with 0.5 mL of diluent (2 mg per 0.5 mL). Mix by rolling the vial gently in your hands for 30 seconds.
Can I take it every day?
+
-
Tesamorelin injection comes as a powder to be mixed with the liquid provided with your medication and injected subcutaneously (under the skin). It is injected once a day. Use it at around the same time every day.
What happens when you stop using it?
+
-
Usually, discontinuation of it results in a relapse of visceral adiposity.
Hot Tags: tesamorelin powder, China tesamorelin powder manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, desmopressin sublingual tablet, glp1 shot, etelcalcetide structure
